Literature DB >> 8794356

Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo.

D P Sharma1, A J Ramsay, D J Maguire, M S Rolph, I A Ramshaw.   

Abstract

Interleukin-4 (IL-4) promotes the growth of Th2-type cells while down regulating the development of Th1-type cells. It has been suggested that the actions of this factor inhibit Th1-type effector activity in vivo and may underlie the development of diseases normally controlled by cell-mediated immune responses. Here, we show that clearance of recombinant vaccinia viruses (VV) engineered to express the gene for murine IL-4 is markedly delayed in mice compared with control recombinant VV. While antiviral antibody levels and NK activity in mice given control virus or IL-4-expressing virus were similar, antiviral cytotoxic T-lymphocyte responses were profoundly suppressed throughout the course of infection with the latter. Limiting dilution analysis of IL-4-virus-infected spleens revealed a marked reduction in numbers of cytotoxic T-lymphocyte precursors. Furthermore, reverse transcriptase PCR analysis of splenic mRNA prepared from mice infected with the IL-4-expressing VV showed a marked down regulation of IL-12, gamma interferon, and IL-2 gene expression compared with that from mice given control virus. IL-4 also inhibited the production of nitric oxide (NO), a potent mediator of antimicrobial activity. Together, these data show that IL-4 markedly suppresses the development of antiviral cell-mediated immune responses in vivo with deleterious effects on virus clearance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794356      PMCID: PMC190762     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Signal requirements in the step-wise functional maturation of cytotoxic T lymphocytes.

Authors:  G Gromo; R L Geller; L Inverardi; F H Bach
Journal:  Nature       Date:  1987 Jun 4-10       Impact factor: 49.962

Review 2.  Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.

Authors:  G Trinchieri
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

Review 3.  Immunology taught by viruses.

Authors:  R M Zinkernagel
Journal:  Science       Date:  1996-01-12       Impact factor: 47.728

4.  Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors.

Authors:  S Chouaib; J Chehimi; L Bani; N Genetet; T Tursz; F Gay; G Trinchieri; F Mami-Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 5.  Acquisition of lymphokine-producing phenotype by CD4+ T cells.

Authors:  R A Seder; W E Paul
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

Review 6.  T cell response to viral and bacterial infection.

Authors:  R V Blanden
Journal:  Transplant Rev       Date:  1974

7.  The role of interleukin-6 in mucosal IgA antibody responses in vivo.

Authors:  A J Ramsay; A J Husband; I A Ramshaw; S Bao; K I Matthaei; G Koehler; M Kopf
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

8.  Interleukin-12 gene expression after viral infection in the mouse.

Authors:  J P Coutelier; J Van Broeck; S F Wolf
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  Virus-specific CD8+ cells can switch to interleukin 5 production and induce airway eosinophilia.

Authors:  A J Coyle; F Erard; C Bertrand; S Walti; H Pircher; G Le Gros
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

10.  Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles.

Authors:  M Croft; L Carter; S L Swain; R W Dutton
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

View more
  48 in total

1.  Creation of killer poxvirus could have been predicted.

Authors:  A Müllbacher; M Lobigs
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus.

Authors:  J E Fischer; J E Johnson; R K Kuli-Zade; T R Johnson; S Aung; R A Parker; B S Graham
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 3.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

4.  Genome-wide analysis of polymorphisms associated with cytokine responses in smallpox vaccine recipients.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Iana H Haralambieva; Robert A Vierkant; Gregory A Poland
Journal:  Hum Genet       Date:  2012-05-19       Impact factor: 4.132

5.  IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine.

Authors:  Sandra A Calarota; Anlan Dai; Jeffrey N Trocio; David B Weiner; Franco Lori; Julianna Lisziewicz
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

Review 6.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

7.  Modification of the Sendai virus-specific antibody and CD8+ T-cell responses in mice homozygous for disruption of the interleukin-4 gene.

Authors:  X Y Mo; M Y Sangster; R A Tripp; P C Doherty
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

8.  Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.

Authors:  R J Jackson; A J Ramsay; C D Christensen; S Beaton; D F Hall; I A Ramshaw
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

9.  Cytokines, Antibodies, and Histopathological Profiles during Giardia Infection and Variant-Specific Surface Protein-Based Vaccination.

Authors:  Marianela C Serradell; Pablo R Gargantini; Alicia Saura; Sergio R Oms; Lucía L Rupil; Luciana Berod; Tim Sparwasser; Hugo D Luján
Journal:  Infect Immun       Date:  2018-05-22       Impact factor: 3.441

10.  Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.

Authors:  Douglas W Grosenbach; Robert Jordan; David S King; Aklile Berhanu; Travis K Warren; Dana L Kirkwood-Watts; Shanthakumar Tyavanagimatt; Ying Tan; Rebecca L Wilson; Kevin F Jones; Dennis E Hruby
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.